Skip to main content
. Author manuscript; available in PMC: 2025 Apr 1.
Published in final edited form as: Dev Med Child Neurol. 2023 Sep 28;66(4):456–468. doi: 10.1111/dmcn.15747

TABLE 5.

Developmental and other neurological disorders diagnosed in individuals with CDD compared with those with other infantile-onset epilepsies with a suspected or defined genetic etiology

Clinical feature CDD Other infantile-onset epilepsies p Other infantile-onset no genetic diagnosis p Other infantile-onset confirmed genetic epilepsies p

n (%) n (%) n (%) n (%)
Total cohort 137a 313b 203c 110d
Autism (≥3 years) 10 (14.7)f 54 (25.6) 0.069 40 (28.4) 0.037 14 (20.0) 0.502
Intellectual disability (≥5 years) 64 (100) 104 (77.0) e <0.001 78 (78.0) e <0.0001 26 (74.3) f <0.001
 Mild/moderate 1 (1.6) 28 (26.9) <0.001 19 (24.4) <0.0001 9 (34.6) <0.001
 Severe/profound 63 (98.4) 70 (67.3) 54 (69.2) 16 (61.5)
 Unknown 0 6 (5.8) 5 (6.4) 1 (3.8)
Development <0.001 <0.001 <0.001
 Normal development 0 47 (15.2) 34 (16.9) 13 (11.9)
 Global developmental delay 133 (100) 240 (77.4) 154 (76.6) 86 (78.9)
 Delays in one area only 0 23 (7.4) 13 (6.5) 10 (9.2)
Global developmental delay (≥1 year) 121 (100) 227 (79.1) <0.001 144 (78.3) <0.001 83 (80.6) <0.001
Any developmental regression 69 (52.3) 89 (29.0) <0.001 57 (28.6) <0.001 32 (29.6) <0.001
 No regression 63 (47.7) 218 (71.0) 142 (71.4) 76 (70.4)
 Yes, independent of seizures/change in EEG 13 (9.8) 10 (3.3) 6 (3.0) 4 (3.7)
 Yes, in the setting of epileptic encephalopathy 35 (26.5) 73 (23.8) 50 (25.1) 23 (21.3)
 Yes, unknown setting 21 (15.9) 6 (2.0) 1 (0.5) 5 (4.6)
Stereotypies 89 (68.5) 35 (11.3) <0.001 22 (10.9) <0.001 13 (12.0) <0.001
Any movement disorder 34 (28.8) f 52 (16.7) 0.005 28 (13.8) 0.001 24 (22.0) 0.241
 Choreoathetosis 11 (9.3) 14 (4.5) 7 (3.5) 7 (6.2)
 Dystonia (paroxysmal) 13 (11.0) 12 (3.8) 6 (3.0) 6 (5.3)
 Tremors 3 (2.5) 7 (2.2) 4 (2.0) 3 (2.7)
 Dyskinesias 6 (5.1) 8 (2.6) 4 (2.0) 4 (3.5)
 Tics 0 3 (1.0) 2 (1.0) 1 (0.9)
 Non-epileptic myoclonus 1 (0.8) 8 (2.6) 5 (2.5) 3 (2.7)
 Ataxia 1 (0.8) 4 (1.3) 2 (1.0) 2 (1.8)
 Other 4 (3.4) 4 (1.3) 3 (1.5) 1 (0.9)
Cerebral visual impairment (≥2 years) 90 (87.4) 71 (28.0) <0.001 49 (29.3) <0.001 22 (25.3) <0.001

The p-values were calculated from χ2 or Fisher’s exact tests compared with the CDD cohort. Significant clinical features are set in bold type after Benjamini–Hochberg correction on the basis of a false discovery rate of 0.2.

a

Numbers for cohorts with age cutoffs: ≥1 year = 123, ≥2 years = 105, ≥3 years = 89, ≥5 years = 64.

b

Numbers for cohorts with age cutoffs: ≥1 year = 288, ≥2 years = 260, ≥3 years = 218, ≥5 years = 163.

c

Numbers for cohorts with age cutoffs: ≥1 year = 185, ≥2 years = 169, ≥3 years = 147, ≥5 years = 115.

d

Numbers for cohorts with age cutoffs: ≥1 year = 103, ≥2 years = 91, ≥3 years = 71, ≥5 years = 48.

Features with missing data >10% noted

e

11–19% missing

f

20–29% missing.

Abbreviations: CDD, CDKL5 deficiency disorder; CDKL5, cyclin-dependent kinase-like 5; EEG, electroencephalogram.